ABCL is trading 4.9% up now at $7.97 after several volatile sessions in late June and early July. Recent gains have followed earlier positive sentiment tied to its biotech pipeline and Q1 earnings beat, but there is no fresh, company-specific news or analyst call clearly linked to today’s move. The stock appears to be rebounding alongside a generally positive U.S. market tone, with major indexes moderately higher.